FDA's Policy Development and Coordination Staff

Director David Adams is leaving the agency in May to join the Washington, D.C. office of Morgan, Lewis & Bockius, an international law firm. Adams, 42, joined FDA in 1978 as associate chief counsel for enforcement and trial attorney. From 1985 to 1992, Adams served as associate chief counsel for drugs and, in January 1992, went to the Office of the Commissioner. As an FDA litigator, Adams spearheaded a variety of enforcement and defensive cases including the 1991 consent decree with Syntex over Naprosyn promotions. He was the primary attorney handling the generic drug controversies and the final regs implementing Title I of the Waxman/Hatch Act. Adams also was involved in development of FDA policies on application integrity, industry-supported scientific and educational activities, pharmacist compounding and accelerated drug approval